Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Items 601–700 of 864
Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors
Ehehalt, F., Franke, E., Pilarsky, C. P., & Grützmann, R. (2010) · Cancers · doi:10.3390/cancers2041901 · Cited by 6
Maladie de von Hippel-Lindau : progrès génétiques et cliniques récents
Richard, S., Parker, F., Aghakhani, N., Allegre, G., Portier, F., David, P., & Marsot-Dupuch, K. (2005) · Journal of Neuroradiology · doi:10.1016/s0150-9861(05)83133-5 · Cited by 8
The role of ubiquitination and deubiquitination in urological tumours
Gan, L., Luo, P., Zou, J., Li, W., Chen, Q., Cheng, L., Zhang, F., Zhong, H., Zheng, L., & Qian, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1532878 · Cited by 5
Ma, J., Wang, X., & Sun, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782874 · Cited by 11
The clinical landscape of HIF2α inhibitors in oncology
Saad, E., Machaalani, M., McDermott, D. F., & Choueiri, T. K. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01145-y · Cited by 6
Sarkadi, B., & Patócs, A. (2019) · Experientia supplementum · doi:10.1007/978-3-030-25905-1_8 · Cited by 6
Shult, C. G., Gunderson, K., Coffey, S. J., McNally, B., Brandt, M., Smith, L. S., Steczynski, J. E., Olerich, E. R., Schroeder, S. E., Severson, N. J., et al. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2404531 · Cited by 5
Heritable and Syndromic Pheochromocytoma and Paraganglioma
Kopp, P. A. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_4 · Cited by 5
Faiyaz‐Ul‐Haque, M., Jamil, M., Aslam, M. Q., Abalkhail, H. A., Al‐Dayel, F., Basit, S., Nawaz, Z., & Zaidi, S. H. E. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.02.006 · Cited by 9
Zhang, K., Yang, W., Ma, K., Qiu, J., Li, L., Xu, Y., Zhang, Z., Yu, C., Zhou, J., Gong, Y., et al. (2022) · Journal of Medical Genetics · doi:10.1136/jmg-2022-108633 · Cited by 5
Low-molecular-weight S-nitrosothiols and blood vessel injury
Marsden, P. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33136 · Cited by 5
von Hippel–Lindau-associated malignancies: Mechanisms and therapeutic opportunities
Kaelin, W. G. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.04.003 · Cited by 8
Self-citationExperimental and Computational Studies Indicate Specific Binding of pVHL Protein to Aurora-A Kinase
Ferchichi, I., Stambouli, N., Marrackchi, R., Arlot‐Bonnemains, Y., Prigent, C., Fadiel, A., Odunsi, K. O., Elgaaïed, A. B. A., & Hamza, A. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp909869g · Cited by 5
Molecular Genetics and Cancer Biology
Gonzalgo, M. L., & Meeker, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00018-9 · Cited by 5
Panarsky, R., Crooks, D. R., Lane, A. N., Yang, Y., Cassel, T., Fan, T. W. ‐., Linehan, W. M., & Moscow, J. A. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00214-9 · Cited by 5
Chrabańska, M., Szweda-Gandor, N., & Drozdzowska, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043778 · Cited by 5
Stolle, C. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-33227-7_23 · Cited by 5
Targeted Therapy in Renal Cell Carcinoma
Jonasch, E., & Tannir, N. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_15 · Cited by 5
Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines
Rodriguez, A. R., & Fishman, M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.2979 · Cited by 5
Genetics of Renal Cell Carcinoma
Ball, M. W., & Linehan, W. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92309-3_3 · Cited by 5
Schrader, K. A., Sharaf, R., Alanee, S. R., & Offit, K. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00012-6 · Cited by 5
Biological insights from the whole genome analysis of human embryonic stem cellsPreprint
Merkle, F. T., Ghosh, S. D., Genovese, G., Handsaker, R. E., Kashin, S., Karczewski, K. J., O’Dushlaine, C. T., Pato, C. N., Pato, M. T., MacArthur, D. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.26.337352 · Cited by 5
Feilen, T., Rogg, M., Andreev, G., Pinter, N., Wess, M., Koessinger, A. L., Diel, N., Neumann‐Haefelin, E., Ganner, A., Grabbert, M. T., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101214 · Cited by 6
Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan
Rodríguez-Alvarado, M., Qin, Q., Tambar, U. K., & Brugarolas, J. (2026) · Cancer · doi:10.1002/cncr.70239 · Cited by 6
Tissue-Based Immunohistochemical Markers for Diagnosis and Classification of Renal Cell Carcinoma
Qu, L. G., Thirugnanasundralingam, V., Bolton, D. M., Finelli, A., & Lawrentschuk, N. (2020) · Société Internationale d’Urologie Journal · doi:10.48083/mqye9599 · Cited by 4
Han, X. Y., Shang, D., Han, T., Xu, X., & Tian, Y. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1691 · Cited by 4
Subcellular Dynamics of The VHL Tumor Suppressor: On The Move for HIF Degradation
Khacho, M., & Lee, S. (2009) · Future Oncology · doi:10.2217/14796694.5.1.85 · Cited by 5
Jarrell, S. T., Oldfield, E. H., & Lonser, R. R. (2008) · Springer eBooks · doi:10.1007/978-3-211-69500-5_6 · Cited by 4
VHL-deficiency leads to reductive stress in renal cells
Vellama, H., Eskla, K., Eichelmann, H. Y., Hüva, A., Tennant, D. A., Thakker, A., Roberts, J., Jagomäe, T., Porosk, R., Laisk, A., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.029 · Cited by 4
A novel mutation in the VHL gene in a Chinese family with von Hippel-Lindau disease
Wu, X., Chen, L., Zhang, Y., Xie, H., Xue, M., Wang, Y., & Huang, H. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0716-4 · Cited by 4
Von Hippel-Lindau disease (VHL-syndrome)
Юкина, М. Ю., Tiulpakov, A. N., Troshina, E. A., & Beltsevich, D. G. (2012) · Problems of Endocrinology · doi:10.14341/probl201258234-41 · Cited by 5
Trigo, J. M., & Bellmunt, J. (2008) · Medicina Clínica · doi:10.1157/13117476 · Cited by 5
Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy
Prabhu, V. V., & Guruvayoorappan, C. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2010.545418 · Cited by 4
Metastatic Renal Cell Cancer—Systemic Therapy
Joshi, A., Sahu, A., Noronha, V., Patil, V., & Prabhash, K. (2018) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-018-0721-2 · Cited by 4
Stolle, C. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_26 · Cited by 4
Stolle, C. A. (2008) · Springer eBooks · doi:10.1007/978-0-387-87366-4_9 · Cited by 4
The skeleton: an overlooked regulator of systemic glucose metabolism in cancer?
Ronghe, R., & Tavares, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1481241 · Cited by 5
Lozano, L. P., Jensen, R., Jennisch, M. K., Pandala, N. G., Jamshidi, F., Boldt, H. C., Tucker, B. A., & Binkley, E. M. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101359 · Cited by 4
The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls
Morais, C., David, W., & Glenda, C. (2012) · InTech eBooks · doi:10.5772/27009 · Cited by 3
Morphological and hemodynamic analysis of the patient-specific renal cell carcinoma models
Huang, X., Liu, D., & Wang, X. (2021) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2021.110636 · Cited by 4
von Hippel–Lindau syndrome and steroid cell tumor of the ovary: A case report
Delgado, A. D. L., Villegas-Rubio, J. A., Mora, E. H., & Fernández‐Velasco, A. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30543 · Cited by 3
Glucose deprivation impairs hypoxia-inducible factor-1α synthesis
Hubert, M., Stuart, S. E., & Ohh, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01484-1 · Cited by 5
Targeted Approaches to Drug Development
Stegmaier, K., & Sellers, W. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00004-2 · Cited by 4
Minnella, A. M., Pagliei, V., Maceroni, M., Federici, M., Gambini, G., & Caporossi, A. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1787-8 · Cited by 3
Gharaibeh, N. S., Shively, S. B., & Vortmeyer, A. O. (2022) · Medicina · doi:10.3390/medicina58121725 · Cited by 3
Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors
Fishbein, L. M., & Nathanson, K. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1798-3_2 · Cited by 3
C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma
Vankayala, H. M., LoRusso, P. M., & Vaishampayan, U. N. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_10 · Cited by 4
Clinical presentation and mutation analysis of VHL disease in a large Chinese family
Zhang, Q. H., Li, D., Kang, P., Ji, N., Yang, J. J. J., Liu, W., Zhang, L., & Jia, G. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1924-9 · Cited by 3
Regulation of Angiogenesis by Hypoxia-Inducible Factors
Hayakawa, H., & Shibasaki, F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5857-9_6 · Cited by 3
Williams, B. J., Schefler, A. C., & Murray, T. G. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/45005 · Cited by 3
Nervous System Manifestations of von Hippel-Lindau Disease
Huntoon, K. M., & Lonser, R. R. (2014) · Cited by 3
A c.464T>A mutation in VHL gene in a Chinese family with VHL syndrome
LuJun, Y., & LiuJian, L. (2013) · Cited by 3
Hereditary Renal Cell Carcinoma
Baba, M., Schmidt, L. S., & Linehan, W. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_2 · Cited by 4
Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers
Thompson, J. M., Landman, J., & Razorenova, O. V. (2017) · Small GTPases · doi:10.1080/21541248.2017.1336193 · Cited by 6
Bissler, J. J. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7784-0_3 · Cited by 5
Neurofibromatosis and other genetic syndromes
Jost, S. C., & Gutmann, D. H. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00009-4 · Cited by 4
Neckers, L., Ricketts, C. J., & Linehan, W. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt240 · Cited by 3
Franziscus, C. A., Ritz, D., Kappel, N. C., Solinger, J. A., Schmidt, A., & Spang, A. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13771 · Cited by 2
Clinical characteristics and surgical strategy of sporadic cerebellar hemangioblastomas
Hao, G., Zhang, B., Li, Y., Wu, Y., Han, Y., & Chen, X. '. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2781 · Cited by 5
Retinal vascular proliferation with fibrotic regression in von Hippel–Lindau disease
Chen, J., Chou, H., Chao, A., Lai, C., & Sagoo, M. S. (2025) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo-d-24-00116 · Cited by 2
Analysis of von Hippel–Lindau Tumor Suppressor as a Mediator of Cellular Oxygen Sensing
Masson, N., & Ratcliffe, P. J. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)81021-8 · Cited by 2
Rastaldi, M. P. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl776 · Cited by 2
Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions
Yue, L., Wan, W., Xu, P., Li, L., Wang, C., Zhang, Y., Xu, H., Zhang, R., Hu, J., Lu, W., et al. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_7 · Cited by 2
Yoon, Y. (1994) · Oncology Reports · doi:10.3892/or_00000127 · Cited by 73
Fabbro, S. D., Cicinelli, M. V., Lattanzio, R., Bousyf, S., Bruno, L., Antropoli, A., Bianco, L., Bruschi, E., Arrigo, A., Pipitone, G. B., et al. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100846 · Cited by 2
Zhou, J., & Li, X. (2018) · Springer eBooks · doi:10.1007/978-3-319-59680-8_178 · Cited by 2
Molecular Biology of Clear Cell Renal Carcinoma
Kaelin, W. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_2 · Cited by 2
Self-citationTherapeutic Strategies that Target the HIF System
Cook, K. M., & Schofield, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_32 · Cited by 2
Hypoxic Regulation of Angiogenesis by HIF-1
Charlesworth, P. J. S., & Harris, A. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_15 · Cited by 4
The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Peruzzi, B., Lattouf, J., & Bottaro, D. P. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_18 · Cited by 2
EGFR and HER2: Relevance in Renal Cell Carcinoma
Kalra, S., & Jonasch, E. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_14 · Cited by 3
Rajasekaran, R., Sudandiradoss, C., Doss, C. G. P., Singh, A., & Sethumadhavan, R. (2008) · Mammalian Genome · doi:10.1007/s00335-008-9143-8 · Cited by 3
Oosterwijk‐Wakka, J. C., Boerman, O. C., Mulders, P., & Oosterwijk, E. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_13 · Cited by 2
Special Edition EAU-ICUD - Review - Kidney Cancer Current Pathology Keys of Renal Cell Carcinoma
Ferran Algaba, B., Akaza, H., Martignoni, G., Moch, H., Montironi, R., & Reuter, V. E. (2011) · Cited by 2
La maladie de von Hippel-Lindau (VHL): diagnostic et traitement
Müller, H., Bürki, N., Gillessen, S., Gürtler, M., Imhof, H., Keller, U., Messmer, E. P., Schumacher, M., & Trutmann, E. (2006) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2006.05763 · Cited by 2
Molecular and Cellular Mechanisms of Angiogenesis
Ferozepurwalla, Z., Merzah, J., Thielemans, L., & Birdsey, G. M. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-24219-0_18 · Cited by 2
Biostatistics of VHL-Gene Transfection in the Health Informatics Analysis of Renal Cell Carcinoma
Gong, Y., Wang, D., & Wang, W. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5297580 · Cited by 2
Li, Y., Xin, X., Song, W., Zhang, X., Chen, S., Wang, Q., Li, A., & Li, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.951054 · Cited by 4
Neurofibromatosis type1, type 2, tuberous sclerosis and Von Hippel-Lindau disease
Elbeltagy, M., & Abbassy, M. A. (2023) · Child s Nervous System · doi:10.1007/s00381-023-06160-3 · Cited by 3
T-cell lymphoma with von Hippel-Lindau disease: a rare case report and review of literature.
Lou, L., Shen, H., Lin, J., Yan, Y., Yan, P., Lu, J., Qu, X., & Hai-qiong, J. (2015) · PubMed Central · Cited by 2
Keith, B., & Simon, M. C. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10018-4 · Cited by 4
Ubiquitin Signaling and Cancer Pathogenesis
Haglund, K., & Đikić, I. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch1 · Cited by 2
Martin, B., Chesnel, F., Delcros, J., Jouan, F., Couturier, A., Dugay, F., Goff, X. L., Patard, J., Fergelot, P., Vigneau, C. M., et al. (2014) · PLoS ONE · doi:10.1371/annotation/d506055a-d16b-4c0c-aef6-ad39e91a3b8d · Cited by 2
Structural analysis of EPOP BC-box binding to the elongin BC complex
Kim, S., Yeo, H., & Lee, B. I. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151691 · Cited by 1
McKay, R. R., Eapen, R. S., Wulff-Burchfield, E. M., & Hofman, M. S. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473862 · Cited by 1
Yuan, J., Maitra, S., Antoniou, E., Zhu, J., Li, W., Demirel, I. S., Toskas, K., Martinez, I. L., Ozcimen, L., Lindehell, H., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516922122 · Cited by 1
Wang, Q., Huang, J., Zhao, Z., Su, Y., Wu, N., Yang, S., Shen, W., Sai, N., & Han, W. (2025) · Current Oncology · doi:10.3390/curroncol32110633 · Cited by 1
Renal Tumors in Patients with von Hippel-Lindau Disease: "State of Art Review"
Alvarez, M., Martínez‐Piñeiro, L., & Ríos, E. (2011) · InTech eBooks · doi:10.5772/26332 · Cited by 1
Angiogenesis inhibition in renal cell cancer
Leonhartsberger, N. (2014) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-014-0160-x · Cited by 1
A novel germline mutation of theVHLgene in a Greek family with Von Hippel–Lindau disease
Peppa, Μ., Kamakari, S., Boutati, E. I., Nikolopoulos, P., Giatzakis, C., Economopoulos, T., Hadjidakis, D., & Raptis, S. (2009) · BMJ Case Reports · doi:10.1136/bcr.02.2009.1574 · Cited by 1
Risque hémorragique et anti-angiogéniques
Ayllon, J., & Pignot, G. (2010) · The French Journal of Urology · doi:10.1016/s1166-7087(10)70020-8 · Cited by 1
The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies
Kaelin, W. G., & George, D. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_5 · Cited by 1
Self-citationA Case of von Hippel-Lindau Disease Presenting with Pancreatic Neuroendocrine Tumor
Ohn, J. H., Kim, J.-H., Lee, H. J., Seo, W., Hwangbo, Y., Hong, E. S., Park, J. J., & Kim, S. Y. (2011) · Endocrinology and Metabolism · doi:10.3803/enm.2011.26.1.89 · Cited by 1
Lombardi, G., Zustovich, F., Zovato, S., Fiore, D., Cappetta, A., & Pastorelli, D. (2009) · Oncology Reviews · doi:10.1007/s12156-009-0013-8 · Cited by 1
Molecular Aspects of the Warburg Effect
Balding, E., Ververis, K., & Karagiannis, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0706-9_13 · Cited by 2
THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN AND KIDNEY CANCER
Kaelin, W. G., & Ma, B. (2007) · Medicina-buenos Aires · Cited by 1
Self-citationSurgical treatment of von Hippel-Lindau disease complicated by retinal detachment: a clinical case
Neroev, V. V., Ilyukhin, P. A., Ryabina, M. V., & Novikova, A. Y. (2018) · Russian Ophthalmological Journal · doi:10.21516/2072-0076-2018-11-1-85-92 · Cited by 1
Molecular Abnormalities in Kidney Cancer
Signoretti, S., Choueiri, T. K., & Kaelin, W. G. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00039-1 · Cited by 2
Self-citationHarbour, J. W., & Onken, M. D. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3167-3.50010-3 · Cited by 1
Pancreatic Neuroendocrine Neoplasms
Asa, S. L., & Klimstra, D. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-54391-4_11 · Cited by 1
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.